Manipulating PTEN, microRNA, and PTENP1 levels through therapeutic targeting represents a new frontier in cancer treatment, suggesting the potential to treat various cancer types if precise therapeutic targeting successfully surpasses the first phase of clinical trials in humans. The gene discussed is PTEN; the disease is cancer.